title: [Central giant cell granuloma in children: Presentation of different therapeutic options].
abstract: Central giant cell granuloma (CGCG) is a benign tumor that may be subdivided in a non-aggressive form and an aggressive form. In aggressive forms, tumor size and high recurrence risk need large surgical resections. In order to minimize surgical morbidity, especially in children, medical treatments acting on the tumor proliferation are currently being assessed: steroids (triamcinolone), anti-osteoclastic drugs (calcitonine, alendronate, denosumab), anti-angiogenic drugs (interferon α). However to date, there is no evidence for any superiority of medical over surgical treatment. Complete response is rarely obtained and additional surgery is often necessary to remove the tumor in case of tumor progression, to remove a remnant or to remodel bone. Moreover, these drugs have frequent local or systemic side effects such as osteonecrosis and growth deficiencies.
authors.affiliation: Service de chirurgie maxillo-faciale, stomatologie et chirurgie plastique de la face, université d'Auvergne, NHE, CHU de Clermont-Ferrand, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand, France; UMR Inserm/UdA, U1107, neuro-dol, trigeminal pain and migraine, faculté de chirurgie dentaire, BP 10448, 63000 Clermont-Ferrand, France. Electronic address: nphamdang@chu-clermontferrand.fr.
authors.forename: N
authors.initials: N
authors.lastname: Pham Dang
authors.affiliation: Service de chirurgie maxillo-faciale, stomatologie et chirurgie plastique de la face, université d'Auvergne, NHE, CHU de Clermont-Ferrand, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand, France.
authors.forename: M
authors.initials: M
authors.lastname: Longeac
authors.affiliation: Service de chirurgie maxillo-faciale, stomatologie et chirurgie plastique de la face, université d'Auvergne, NHE, CHU de Clermont-Ferrand, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand, France.
authors.forename: M
authors.initials: M
authors.lastname: Picard
authors.affiliation: Service d'odontologie, CHU de Clermont-Ferrand, 63003 Clermont-Ferrand, France.
authors.forename: L
authors.initials: L
authors.lastname: Devoize
authors.affiliation: Service de chirurgie maxillo-faciale, stomatologie et chirurgie plastique de la face, université d'Auvergne, NHE, CHU de Clermont-Ferrand, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand, France; UMR Inserm/UdA, U1107, neuro-dol, trigeminal pain and migraine, faculté de chirurgie dentaire, BP 10448, 63000 Clermont-Ferrand, France; Faculté de médecine, université d'Auvergne, Clermont université, BP 10448, 63000 Clermont-Ferrand, France.
authors.forename: I
authors.initials: I
authors.lastname: Barthélémy
mesh_terms: D019386:Alendronate / Q000627:therapeutic use; D002116:Calcitonin / Q000627:therapeutic use; D002648:Child; D000069448:Denosumab / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006101:Granuloma, Giant Cell / Q000628:therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008336:Mandibular Diseases / Q000628:therapy*; D057909:Orthognathic Surgery; D012074:Remission Induction
chemical_list: D005938:Glucocorticoids; D000069448:Denosumab; D002116:Calcitonin; D007372:Interferons; D019386:Alendronate
keywords: Alendronate; Calcitonine; Corticothérapie; Denosumab; Granuloma giant cell; Granulome central à cellules géantes; Interferon; Steroids